Work

Proglumide, gemcitabine (GEM), and nab-paclitaxel (NAB-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): Results of the phase 1 PROGEM trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4202

Authors: Jill P. Smith, Marcus Smith Noel, Reetu Mukherji, John L. Marshall, Princess Jones, Gakiza Christal Nkulikiyimana, Hong Cao, Wenqiang Chen, Bhaskar Kallakury, John Kwagyan, Benjamin Adam Weinberg

Institutions: Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Howard University

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pancreatic Cancer Action Network

OpenAlex ID: W7162554597

Cites:

Cited by:

Related to: